1. Introduction {#sec1}
===============

Common polymorphisms at multiple blood pressure-related loci from distinct biological pathways are likely to contribute to the genetic component of essential hypertension (EH) in humans \[[@B1]--[@B3]\]. Although previous evidence suggests that multilocus effects may account for a considerable proportion of the unexplained variance of complex traits, the role of multilocus effects in blood pressure traits still remains underexplored \[[@B1]\].

Approximately 4 million Africans were brought to Brazil as slaves over a period of four centuries. Before the abolition of slavery in Brazil (in 1888), many communities, named *quilombos* (presently known as *quilombo* remnants), were founded in isolated areas, in different Brazilian regions, by either runaway or abandoned African slaves \[[@B4]--[@B6]\]. Recent changes in lifestyle of current *quilombos*, such as a decrease in the intensity of agricultural activities and the nutrition transition, are associated with a larger frequency of common diseases such as obesity and essential hypertension \[[@B7], [@B8]\]

In this paper, we present the results of a carefully conducted family-based association study (652 participants from 97 informative families) in semi-isolated Brazilian populations of African ancestry, which includes individuals from remnants of *quilombos*. We hypothesized that multilocus effects between or among seven widely studied polymorphisms in six genes of major importance for blood pressure regulation might modulate the risk of essential hypertension in this peculiar population, characterized by historical inbreeding and high prevalence of cardiovascular risk factors \[[@B8]\].

2. Material and Methods {#sec2}
=======================

2.1. Population Investigated and Phenotyping {#sec2.1}
--------------------------------------------

Participants were ascertained from African-derived Brazilian populations named *quilombos*, which encompass partially genetically isolated communities \[[@B9], [@B10]\]. These communities represent an interesting target group for the study of cardiovascular phenotypes, since recent changes in their lifestyle, such as a decrease in the intensity of agricultural activities and nutrition transition, are associated with a higher frequency of common diseases such as obesity and essential hypertension \[[@B7], [@B8]\]. Importantly, *quilombos*share a particularly homogeneous rural lifestyle and environment. Further information on these populations are found elsewhere \[[@B8]--[@B10]\].

Briefly, the sample consisted of individuals aged over 17 years with clinical and anthropometric data. Participants were sampled from 12 *quilombo*communities (Abobral, Galvão, São Pedro, Pedro Cubas, André Lopes, Nhunguara, Sapatu, Pilões, Ivaporunduva, Maria Rosa, Poça, and Reginaldo), located in the Vale do Ribeira region, São Paulo State (Southern Brazil). Figure S1 (of Supplementary Material available online at doi:40.1155/2012/859219.) presents the numbers of participants at each stage of the study.

Clinical evaluation occurred at multiple visits performed between 2003 and 2010. Due to the fact that *quilombos* are isolated populations, a detailed clinical evaluation was not feasible. However, participants with diabetes or suspected secondary forms of hypertension were excluded.

Blood pressure was measured after 15 min of rest in a sitting position. Two measurements were obtained by a physician from each participant at 5 min intervals. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) values were means of the two physician-obtained measurements.

The primary phenotype was the risk of essential hypertension classified according to the World Health Organization (WHO) criteria (SBP ≥ 140 and/or DBP ≥ 90 and/or use of antihypertensive medication). Blood pressure was also evaluated as a continuous trait. In order to avoid shrinkage in estimated effects for continuous variables, blood pressure levels in participants taking antihypertensive drugs were adjusted by adding 15 mmHg and 10 mmHg to the SBP and DBP, respectively, as recommended previously \[[@B11]\].

Normotensive control participants were defined as those individuals with a SBP \< 140 and DBP \< 90 and no history of use of antihypertensive drugs.

2.2. Genetic Variants Studied {#sec2.2}
-----------------------------

We used the same rational described previously to choose the set of seven variants from six genes \[[@B8]\]. Briefly, the studied polymorphisms were chosen based on the fact that they represent examples of polymorphisms directly involved in blood pressure pathways, but that the cumulative evidence suggests either lack of effect or conflicting (i.e., heterogeneous) results across populations \[[@B12]\]. Our hypothesis was that these variants may not display individual effects, but might interact with each other in order to modulate the variance of blood pressure-related traits.

We hypothesized that seven variants from six major candidate genes directly involved in the (1) renin-angiotensin-aldosterone system: angiotensin-I-converting-enzyme (*ACE*, insertion/deletion in intron 16---rs1799752), and angiotensinogen (*AGT*, M235T---rs669); (2) sodium balance: *β*-adducin (*ADD2*, c.-154 + 20128C\>A---rs3755351); (3) NO-dependent vasodilatation: nitric oxide synthase endothelial (*NOS3*, Glu298Asp---rs1799983); (4) intracellular signal transduction (*GNB3*, C825T---rs5443, and G-350A---rs5441); (5) dopaminergic system: G protein-coupled receptor kinase type 4 (*GRK4*, A486V---rs1801058) might be associated with blood pressure traits under a multilocus perspective. Further information on markers investigated is provided in Table S1 (online only material).

2.3. Genotype Determination {#sec2.3}
---------------------------

DNA was extracted from whole blood using standard procedures. Genotypes for the *Alu* insertion in the *ACE* were determined by polymerase chain reaction (PCR) and electrophoresis in agarose gels; all carriers of DD genotype (without *Alu* insertion) were genotyped twice. Genotypes for marker in the *GNB3* (G-350A) were determined by PCR followed by restriction fragment-length polymorphism analyses; all carriers of A allele were regenotyped by direct sequencing. The markers in *AGT*, *NOS3*,*GNB3*(C825T), *ADD2,*and*GRK4* were genotyped following a minisequencing method using the *MegaBace SnuPe Genotyping Kit*(GE Healthcare, UK). Primers sequences are available as Supplementary Material (Table S1, online only material). Positive (previously tested samples with known genotype) and negative (buffer only) controls were included in each batch as a quality control measure. Genotyping was performed blinded to clinical status.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Data were expressed as means ± standard deviation (SD), median (interquartile range), or absolute number (percentage) when appropriate. The *t-*test for independent samples was used to investigate differences between groups for approximately normally distributed variables. When the distribution of the variables was skewed, the nonparametric Mann-Whitney *U*test was applied. Deviations from the Hardy-Weinberg equilibrium were tested by an exact approach \[[@B10]\].

### 2.4.1. Strategy of Analysis {#sec2.4.1}

We performed two approaches of analysis: (i) a family-based design and (ii) an unrelated case-control design (Figure S1, online only material).

### 2.4.2. Family-Based Analysis {#sec2.4.2}

Family-based association test (FBAT) analyses were performed with the FBAT program. The FBAT framework uses a variety of generalized linear models to perform tests similar to the transmission-disequilibrium test, allowing for the analysis of complex pedigrees \[[@B13]\]. We assumed the null hypothesis that there was no linkage and no association. For the risk of essential hypertension, FBAT analyses were run using (i) an offset value equal to zero (unadjusted), (ii) an offset values equal to the disease prevalence in the studied population (analysis with minimized variance), (iii) covariate-adjusted residuals (fully adjusted analysis). For continuous traits, we performed FBAT analyses considering (i) mean centered values (phenotypic mean approach), (ii) analysis with minimized variance (option --o, that is, an offset value that minimizes the variance of the FBAT statistic) and (iii) covariate adjusted-residuals (fully adjusted analysis). Main analyses assumed an additive model of action, whereas results for both dominant and recessive models were computed in sensitivity analyses.

Under a family-based design, we investigate all possible two-way multilocus effects using the recently proposed flexible family-based multifactor dimensionality reduction (FAM-MDR) approach \[[@B14]\]. The current framework of the FAM-MDR procedure focuses on potential multilocus associations for quantitative traits and can be schematically separated in two main stages. In the first stage, approximately normally distributed (family-based) traits are converted into independent, correlation family-free traits using a combination of mixed models and regression approaches. In the second stage, these new traits (residuals) are submitted to the model-based reduction technique (MD-MDR) yielding composite genotypes (i.e. for two loci, there are a total of nine possible composite genotypes) classified as *high risk*, *low risk* or *no evidence* based on the direction and magnitude of the association \[[@B15]\]. FAM-MDR analysis was carried out using a C++ program (available from the original authors). *P* values were computed by a resampling approach with 10,000 permutations. A full description of this technique is presented in detail elsewhere \[[@B14], [@B15]\].

### 2.4.3. Analysis with Unrelated Participants {#sec2.4.3}

In sensitivity analyses, we also performed analysis considering 384 unrelated participants. For single-locus analysis, we used the MAX3 statistic which selects the largest test statistic from the dominant, recessive, and additive models \[[@B16]\]. To examine potential gene-gene interactions, we applied the generalized multifactor dimensionality reduction (GMDR) technique as described in detail elsewhere \[[@B17]\], whereas haplotypic analyses were computed according to the methodology described previously \[[@B18]\]. Data analysis was performed using the Stata 11.0 package (Stata, College Station, TX), R package (version 2.81, <http://www.r-project.org/>), THESIAS 3.1 (<http://ecgene.net/genecanvas/>), and GMDR (version 0.7, <http://sourceforge.net/projects/gmdr/>). Statistical significance was set at the 5% level (one-tailed for GMDR-based models and two-tailed for the remaining tests).

3. Results {#sec3}
==========

3.1. Family-Based Study {#sec3.1}
-----------------------

From a total of 1521 potentially eligible inhabitants across 12 *quilombo* communities, we included 652 participants with complete data, representing approximately 43% of the total *quilombo* population. There were 97 informative families with an average number of subjects per family of 10.5 (ranging from 3 to 313). The largest family with 313 members represents a complex pedigree with a strong historical founder effect. This family has been partitioned accordingly in FBAT analysis. [Table 1](#tab1){ref-type="table"} provides demographic and clinical for the 652 participants included in the family-based study.

The prevalence of essential hypertension (EH) was 40.5% in women and 44.6% in men, a higher frequency when compared to admixed Brazilian populations \[[@B19]--[@B21]\] and African-derived populations \[[@B22]\]. No significant difference in the prevalence of hypertension was observed between genders (*P* = 0.169).

### 3.1.1. FBAT Analysis {#sec3.1.1}

In the single-locus FBAT analysis, no variant was significantly associated with any of the three examined blood pressure-related phenotypes, namely systolic and diastolic blood pressure (SBP and DBP, resp.) levels and EH ([Table 2](#tab2){ref-type="table"}). FBAT-based haplotypic effects also did not show evidence for significant effects of both *GNB3* variants on blood pressure (data not shown).

### 3.1.2. FAM-MDR Analyses {#sec3.1.2}

The family-based multifactor dimensionality reduction (FAM-MDR) method was applied to blood pressure as a continuous phenotype (i.e., both SBP and DBP in mmHg). As shown in [Table 3](#tab3){ref-type="table"}, there was evidence for a marginally significant effect of both *GNB3*variants (C825T and G-350A) on DBP levels (*P* = 0.04).

3.2. Case-Control Study {#sec3.2}
-----------------------

We next performed a case-control study with unrelated subjects only, which yielded a total of 384 unrelated participants, whose clinical characteristics are shown in [Table 4](#tab4){ref-type="table"}.

### 3.2.1. Single-Locus Associations {#sec3.2.1}

[Table 5](#tab5){ref-type="table"} shows the distribution of genotypes and allele frequencies for the seven studied polymorphisms according to hypertension status. There is no evidence of association of any studied variant with hypertension. Similar results were observed for blood pressure as a continuous variable (e.g., SBP and DBP, data not shown).

### 3.2.2. GNB3 Haplotypic Effects {#sec3.2.2}

Haplotypic analyses of both G-350A and C825T *GNB3* variants based on unrelated participants ([Table 6](#tab6){ref-type="table"}) indicated that the haplotype T825/G-350 might be associated with the odds of essential hypertension (OR = 0.586, 95%  CI = 0.358--0.958), although the alternative hypothesis of a better fit for the alternative model (e.g., a model with significant haplotypic effects) failed to be accepted (*P* = 0.152).

### 3.2.3. Multilocus Associations {#sec3.2.3}

GMDR-based models were constructed to exhaustively identify all possible two- to four-locus models that potentially have an influence on the risk of hypertension and/or modulate SBP and DBP levels in *quilombos* ([Table 7](#tab7){ref-type="table"}). These analyses revealed a single two-locus effect between the *NOS3* and *GRK4* variants on DBP levels that was statistically significant (*P =*0.0044) and had a high cross-validation consistency (90%).

4. Discussion {#sec4}
=============

4.1. Findings {#sec4.1}
-------------

It has been shown that analyses focusing on biologically plausible candidate genes might be a strategy to circumvent the problem of limited coverage of current genome-wide association (GWA) platforms. This strategy holds the promise of increasing the density of markers in regions coding for known blood pressure-related effectors that are likely to be missed by GWA studies in hypertension \[[@B23]\].

Here, we present a comprehensive investigation about the potential role of seven variants (from six candidate genes directly involved in the blood pressure regulation) in the susceptibility of essential hypertension in a semi-isolated, African-derived population (*quilombos*). As described previously, *quilombos* may be an important target population for genetic studies of complex diseases, since this population displays peculiar genetic and environmental characteristics \[[@B8]\]. Specifically, *quilombos*are known not only to have a large contribution of African genes, but also strong founder effects, a substantial degree of inbreeding, and high prevalence of essential hypertension as well as overweight \[[@B7]--[@B10], [@B24]\].

Using different methodological approaches (single-locus, haplotypic, and multilocus effects) and study designs (family-based and unrelated case-control designs), our investigation did not suggest an important contribution of the studied markers in the risk of essential hypertension in *quilombos*. However, our data highlight the potential of two multilocus effects: (i) the effect of both *GNB3* variants (C825T and G-350A polymorphisms) on DBP levels in a family-based design and (ii) the significant *NOS3-GRK4*interaction also in relation to DBP levels in the unrelated case-control design.

Meta-analyses addressing the role of the C825T polymorphism at the *GNB3*locus in hypertension provide evidence for heterogeneity in the genetic effects across populations \[[@B25]\] (i.e., effects found in different populations vary in a larger extent from what would be expected by chance alone) \[[@B12]\]. However, the overall evidence suggests a weak, but significant association of 825T allele with an augmented odds of essential hypertension in both European \[[@B25]\] and Chinese populations \[[@B26]\]. Although no systematic evidence exists for the G-350A variant, hints from previous investigations corroborate to the hypothesis of synergistic effects between and among *GNB3*variants on blood pressure levels \[[@B27]\]. Thus, our observations of a putative C825T/G-350A influence on blood pressure levels may serve as a hypothesis-generating finding for further in-depth investigations.

Recently, gene-centric approaches have revealed *NOS3* markers as significant factors influencing blood pressure levels \[[@B28]\]. These observations corroborate previous investigations, which indicated the potential of role of genetic variants in the nitric oxide pathway on the susceptibility of essential hypertension \[[@B2], [@B29]\]. Interestingly, among all two- to four-locus interactions, the *NOS3*-*GRK4*model was the only combination found to achieve nominal significance with an adequate cross-validation consistency. Recently, despite the use of different markers, the *NOS3*-*GRK4* synergistic effect on blood pressure was also observed in an African American sample \[[@B30]\], suggesting that our result may be a genuine association signal rather than a chance finding. The G-protein-coupled receptor kinase 4 (GRK4) is involved in the regulation of sodium balance \[[@B31]\], and genetic variations at the *GRK4*are associated with both impaired natriuresis and salt-sensitive hypertension \[[@B31], [@B32]\]. Thus, a potential biological mechanism underlying the statistical finding from the *NOS3*-*GRK4*model might be the cumulative effect from both pathways. Indeed, a diminished natriuresis along with an impaired endothelium-dependent (i.e., NOS3-dependent) vasodilatation might lead to increased blood pressure levels. Nonetheless, the plausibility of the observed multilocus effects along with its generalizability across different populations requires further and detailed investigations.

4.2. Limitations {#sec4.2}
----------------

Major limitations of our study include: first, the small number of participants investigated, that is, our samples are underpowered to detect typical main effects of genetic variants associated with common traits and second, lack of information on serum lipids as well as accurate information on smoking habits. In fact, lipids were not investigated due to technical restrictions. Furthermore, we observed that there was inaccurate reporting of smoking status by participants mainly due to heterogeneity in the definition of smoking. For example, a high proportion of participants reported to smoke homemade cigarettes, but failed to consider this as a "smoking habit". As a result, both lipids and smoking status were not included in adjusted analyses.

Furthermore, our results should be carefully interpreted because correction for multiple testing was not performed in our analyses. As this is a hypothesis testing study, we considered that correction for multiple testing would be overly conservative and might lead to a substantial loss of statistical power.

Finally, it is worth of mentioning that the present study does not invalidate the hypothesis of gene-gene interactions/multilocus effects between or among the studied variants nor single-loci effects on blood pressure. Our null associations might plausibly be associated with low statistical power and the reduced panel of markers investigated.

5. Conclusions {#sec5}
==============

In conclusion, our results do not support the hypothesis of significant association between the seven investigated variants and the risk of essential hypertension in *quilombos* but highlight potential multilocus association signals that should be investigated in further studies with larger samples.

Supplementary Material {#supplementary-material-sec}
======================

###### 

The supplementary material includes one figure (Figure S1) and one Table (Table S1). Figure S1 shows all the steps in the selection of subjects for the different types of analyses, both family-based studies and case-control studies. Table S1 provides complete information about the molecular markers selected for association studies with phenotypes related to hypertension, including nucleotide sequences of primer pairs and genomic identification of the polymorphisms.

###### 

Click here for additional data file.

###### 

Click here for additional data file.
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###### 

Descriptive statistics of 652 individuals from 12 *quilombo* populations regarding to studied phenotypes.

  *N* = 652            
  ------------------- ---------------
  Age (years)         43.5 (17--91)
  Male (%)            45.6%
  SBP (mmHg)          131.8 ± 25.6
  DBP (mmHg)          82 ± 13.7
  Hypertension\*      41.6%
  BMI (Kg/m^2^)       24.7 ± 4.48
  BMI \> 25 Kg/m^2^   41.9%

\*Hypertension was defined as a SBP ≥ 140 mmHg and/or a DBP ≥ 90 mmHg or use of antihypertensive medications.

###### 

FBAT analysis for blood pressure-related traits in *quilombos*.

  Gene        Variant            rs          *F*           Phenotypes        
  ----------- ------------------ ----------- ------- ----- ------------ ---- ----
  *ACE*       I/D                rs1799752   0.50    NIF   97           93   95
  *P* value   0.774              0.155       0.123                           
  *NOS3*      Glu298Asp          rs1799983   0.16    NIF   63           63   61
  *P* value   0.101              0.050       0.079                           
  *GNB3*      C825T              rs5443      0.58    NIF   86           84   82
  *P* value   0.793              0.417       0.342                           
  *GNB3*      G-350A             rs5441      0.68    NIF   79           76   76
  *P* value   0.063              0.672       0.565                           
  *AGT*       M235T              rs699       0.27    NIF   96           92   94
  *P* value   0.608              0.293       0.579                           
  *ADD2*      c.-154+20128C\>A   rs3755351   0.34    NIF   97           93   95
  *P* value   0.196              0.209       0.137                           
  *GRK4*      A486V              rs1801058   0.24    NIF   70           69   68
  *P* value   0.096              0.229       0.230                           

NIF: number of informative families. *F*: allele frequency for the risk allele. EH: essential hypertension. SBP: systolic blood pressure (mmHG). DBP: diastolic blood pressure (mmHg). All analyses were adjusted for covariates (age, gender, and BMI when appropriate). Similar results were obtained for other FBAT approaches (e.g. prevalence adjusted, mean centered, or minimal variance approaches) (data now shown). All results refer to analyses performed under assumption of an additive model of action. Qualitatively analogous results were observed for other genetic models (e.g., dominant and recessive) (data not shown).

###### 

Best two-locus models from FAM-MDR analyses.

  Phenotype                Model                           *F* test   *P* value
  ------------------------ ------------------------------- ---------- -----------
  SBP                      *GNB3*(C825T), *ADD2*           8.203      0.533
  *GNB3*(C825T), *ACE*     6.318                           0.819      
  *GNB3*(G-350A), *GRK4*   6.043                           0.837      
  *GNB3*(G-350A), *ACE*    4.172                           0.981      
  *ACE*, *ADD2*            3.864                           0.984      
  *NOS3*, *ADD2*           3.146                           0.997      
                                                                      
  DBP                      *GNB3*(C825T), *GNB3*(G-350A)   14.064     0.040
  *GNB3*(C825T), *ACE*     8.500                           0.460      
  *GNB3*(G-350A), *ADD2*   8.014                           0.512      
  *GNB3*(G-350A), *ACE*    7.970                           0.512      
  *NOS3*, *ADD2*           6.763                           0.681      
  *GNB3*(C825T), *ADD2*    6.364                           0.732      

SBP: systolic blood pressure. DBP: diastolic blood pressure.

###### 

Clinical characteristics of the unrelated *quilombo* sample.

                           Normotensives (*n* = 206)   Hypertensives (*n* = 178)   *P* value
  ------------------------ --------------------------- --------------------------- -----------
  Gender                                                                            
   Men                     98 (47.57)                  79 (44.38)                  0.540
   Women                   108 (52.43)                 99 (55.62)                  
  Age (years)              32 (24.5--44.7)             55.7 (42.4--67.4)           \<0.001
  Adjusted SBP (mmHg)^∗^   115.54 ± 12.29              155.85 ± 21.39              \<0.001
  Adjusted DBP (mmHg)^∗^   74.79 ± 7.22                94.84 ± 13.60               \<0.001
  BMI (Kg/m^2^)            23.95 ± 3.89                25.79 ± 4.40                \<0.001

^∗^Adjusted for the antihypertensive use according the proposition by Tobin et al. \[[@B11]\].

###### 

Genotype frequencies for the seven studied polymorphisms in normotensive and hypertensive *quilombo*subjects.

  Gene/Status         Genotype, *n* (%)   *P* HWE       *F*          *P* MAX3           
  ------------------- ------------------- ------------- ------------ ---------- ------- -------
  *ACE*(I/D)          I/I                 I/D           D/D                              
   Hypertensive       39 (21.91)          92 (51.69)    47 (26.40)   0.474      0.518   0.227
   Normotensive       54 (26.21)          92 (44.66)    60 (29.13)                      
  *NOS3*(Glu298Asp)   Glu/Glu             Glu/Asp       Asp/Asp                          
   Hypertensive       127 (71.35)         47 (26.40)    4 (2.25)     0.842      0.150   0.922
   Normotensive       151 (73.30)         50 (24.27)    5 (2.43)                        
  *GNB3*(C825T)       C/C                 C/T           T/T                              
   Hypertensive       42 (23.60)          74 (41.57)    62 (34.83)   0.999      0.592   0.054
   Normotensive       22 (10.68)          111 (53.88)   73 (35.44)                      
  *GNB3* (G-350A)     G/G                 A/G           A/A                              
   Hypertensive       93 (52.25)          60 (33.71)    25 (14.04)   0.028      0.297   0.595
   Normotensive       106 (51.46)         82 (39.81)    18 (8.74)                       
  *AGT* (M235T)       Thr/Thr             Thr/Met       Met/Met                          
   Hypertensive       91 (51.12)          73 (41.01)    14 (7.87)    0.425      0.259   0.482
   Normotensive       123 (59.71)         68 (33.01)    15 (7.28)                       
  *ADD2*(A/C)         A/A                 A/C           C/C                              
   Hypertensive       27 (15.17)          94 (45.63)    83 (46.63)   0.256      0.661   0.565
   Normotensive       22 (10.68)          68 (38.20)    90 (43.69)                      
  *GRK4*(A486V)       Ala/Ala             Ala/Val       Val/Val                          
   Hypertensive       98 (55.06)          72 (40.45)    8 (4.49)     0.893      0.253   0.586
   Normotensive       117 (56.80)         72 (34.95)    17 (8.25)                       

HWE: Hardy-Weinberg equilibrium; *F*: frequency of the risk allele; MAX3: max-statistic; MAX3-based results are adjusted for age, gender, and BMI.

###### 

Analysis of haplotypic effects (G-350A/C825T) on blood pressure-related phenotypes.

  Trait          *N*   Haplotypes               Haplotypic effects   LD measures   LR test                              
  -------------- ----- ------------------------ -------------------- ------------- ----------- ------ ------ ---------- -------
  Hypertension   384   G                        C                    reference     ---         0.40   0.10   5.29 (3)   0.152
  G              T     0.586 (0.358--0.958)     0.033                                                                   
  A              C     0.591 (0.336--1.040)     0.068                                                                   
  A              T     0.865 (0.451-- 1.659)    0.661                                                                   
                                                                                                                        
                                                                     Δ (95% CI)    *P* value                             
                                                                                                                        
  SBP (mmHg)     384   G                        C                    reference     ---         0.40   0.10   7.04 (3)   0.071
  G              T     −2.208 (−6.734--2.318)   0.339                                                                   
  A              C     −0.482 (−5.95--4.986)    0.862                                                                   
  A              T     −1.361 (−7.39--4.67)     0.658                                                                   
                                                                                                                        
                                                                     Δ (95% CI)    *P* value                             
                                                                                                                        
  DBP (mmHg)     384   G                        C                    reference     ---         0.40   0.10   2.82 (3)   0.420
  G              T     −1.247 (−3.878--1.383)   0.352                                                                   
  A              C     −2.328 (−5.447--0.792)   0.143                                                                   
  A              T     −1.996 (−5.596--1.605)   0.277                                                                   

*N*: sample size. OR: odds ratio. EH: essential hypertension. LD: linkage disequilibrium. LR: likelihood ratio. df: degrees of freedom. Δ: expected linear increment in the trait per additional copy of the haplotype (in mmHg). All results refer to the additive model of analysis and are adjusted for age, gender, and BMI. Analyses were also performed under both dominant and recessive models of action, yielding qualitatively analogous results (data not shown). The overall proportion of haplotypes G-350A/C825T in the studied population was 0.197, 0.499, 0.196, and 0.108 for haplotypes GC, GT, AC, and AT, respectively. For the hypertension status, haplotypic frequencies for hypertensive/normotensive participants were as follows: GC: 0.248/0.186, GT: 0.443/0.523, AC: 0.195/0.190 and AT: 0.114/0.10.

###### 

Best predictive models from GMDR analyses.

  Model                                    Test accuracy              CVC   *P* value
  ---------------------------------------- -------------------------- ----- -----------
                                           Hypertension                      
  *GNB3(G-350A), GRK4*                     0.4884                     4     0.5324
  *NOS3, GNB3(C825t), ADD2*                0.5569                     4     0.0792
  *GNB3(C825t), GNB3(G-350A), AGT, GRK4*   0.5850                     3     0.0222
                                                                            
                                           Systolic blood pressure           
  *GNB3(G-350A), GRK4*                     0.5220                     5     0.2644
  *NOS3, GNB3 (G-350A), AGT*               0.5752                     5     0.0444
  *ACE, GNB3(G-350A), ADD2, GRK4*          0.5282                     4     0.2440
                                                                            
                                           Diastolic blood pressure          
  *NOS3, GRK4*                             0.6031                     9     0.0044
  *ACE, ADD2, GRK4*                        0.5677                     3     0.0724
  *ACE, NOS3, GNB3(C825t), GRK4*           0.6347                     6     0.0014

CVC: cross-validation consistency.

[^1]: Academic Editor: Monica Domenech
